NCT00569803View on ClinicalTrials.gov

Subcutaneous Pharmacokinetics of Belatacept

PHASE1CompletedINTERVENTIONAL
Enrollment

153

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
Transplantation
Interventions
DRUG

belatacept

single dose, 116 days

DRUG

Placebo

Subcutaneous injection of placebo solution (product ID: 224818-N000- 029)

Trial Locations (1)

78744

Ppd Development, Austin

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY